COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure (CARNEBI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00517725
Recruitment Status : Completed
First Posted : August 17, 2007
Last Update Posted : September 16, 2010
Information provided by:
Centro Cardiologico Monzino

Brief Summary:

The investigators test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity.

Both could influence exercise capacity in normoxic as well as hypoxic conditions.

Condition or disease Intervention/treatment Phase
Chronic Heart Failure Drug: carvedilol Drug: bisoprolol Drug: Nebivolol Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function
Study Start Date : July 2007
Actual Study Completion Date : May 2010

Arm Intervention/treatment
Active Comparator: Carvedilol Drug: carvedilol
Active Comparator: Bisoprolol Drug: bisoprolol
Active Comparator: Nebivolol Drug: Nebivolol

Primary Outcome Measures :
  1. exercise capacity [ Time Frame: two months ]

Secondary Outcome Measures :
  1. lung diffusion [ Time Frame: two months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic heart failure patients in stable clinical condition

Exclusion Criteria:

  • No comorbidity
  • NYHA class IV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00517725

Layout table for location information
Centro Cardiologico Monzino, University of Milan
Milan, Italy, 20138
Sponsors and Collaborators
Centro Cardiologico Monzino
Layout table for investigator information
Principal Investigator: Piergiuseppe Agostoni, MD, PhD Centro Cardiologico Monzino
Study Chair: Giancarlo Marenzi, MD Centro Cardiologico Monzino
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Piergiuseppe Agostoni, Centro Cardiologico Monzino - Univeristy of Milan Identifier: NCT00517725    
Other Study ID Numbers: R76-CCM S78/407
First Posted: August 17, 2007    Key Record Dates
Last Update Posted: September 16, 2010
Last Verified: September 2010
Keywords provided by Centro Cardiologico Monzino:
lung diffusion
heart failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents
Protective Agents
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists